-
Je něco špatně v tomto záznamu ?
Recent advances in drugs and prodrugs design of chitosan
J Vinsova, E Vavrikova
Jazyk angličtina Země Nizozemsko
Typ dokumentu přehledy
NLK
ProQuest Central
od 2000-01-01 do 2008-12-31
Health & Medicine (ProQuest)
od 2000-01-01 do 2008-12-31
- MeSH
- antibakteriální látky chemie terapeutické užití MeSH
- antioxidancia chemie terapeutické užití MeSH
- chitosan farmakologie chemie terapeutické užití MeSH
- financování organizované MeSH
- molekulární modely MeSH
- molekulární struktura MeSH
- nosiče léků MeSH
- prekurzory léčiv farmakologie chemie terapeutické užití MeSH
- protinádorové látky chemie terapeutické užití MeSH
- racionální návrh léčiv MeSH
- Publikační typ
- přehledy MeSH
The aim of this review is to outline the recent advances in chitosan molecular modeling, especially its usage as a prodrug or drug in a field of antibacterial, anticarcinogenic and antioxidant activity. Polymeric materials like peptides, polysaccharides and other natural products have recently attracted attention as biodegradabile drug carriers. They can optimize clinical drug application, minimize the undesirable drug properties and improve drug efficiency. They are used for the slow release of effective components as depot forms, to improve membrane permeability, solubility and site-specific targeting. Chitosan is such a prospective cationic polysaccharide which has shown number of functions in many fields, including bio medicinal, pharmaceutical, preservative, microbial and others. This article discusses the structure characteristics of chitosan, a number of factors such as degree of polymerization, level of deacetylation, types of quarternisation, installation of various hydrophilic substituents, metal complexation, and combination with other active agents. Biodegradable, non-toxic and non-allergenic nature of chitosan encourages its potential use as a carrier for drug delivery systems in all above mentioned targets. The use of chitosan prodrug conjugates is aimed at the site-specific transport to the target cells use, for example, a spacer tetrapeptide Gly-Phe-Leu-Gly, promotion of drug incorporation into cells via endocytosis, hybridization or synergism of two types of drugs or a drug with a bioactive carrier. The design of chitosan macromolecule prodrugs is also discussed.
- 000
- 03192naa 2200409 a 4500
- 001
- bmc11003707
- 003
- CZ-PrNML
- 005
- 20121127124552.0
- 008
- 110302s2008 ne e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Vinšová, Jana. $7 _AN043807
- 245 10
- $a Recent advances in drugs and prodrugs design of chitosan / $c J Vinsova, E Vavrikova
- 314 __
- $a Faculty of Pharmacy, Charles University, Czech Republic, Heyrovskeho 1203, 500 05 Hradec Kralove. jarmila.vinsova@faf.cuni.cz
- 520 9_
- $a The aim of this review is to outline the recent advances in chitosan molecular modeling, especially its usage as a prodrug or drug in a field of antibacterial, anticarcinogenic and antioxidant activity. Polymeric materials like peptides, polysaccharides and other natural products have recently attracted attention as biodegradabile drug carriers. They can optimize clinical drug application, minimize the undesirable drug properties and improve drug efficiency. They are used for the slow release of effective components as depot forms, to improve membrane permeability, solubility and site-specific targeting. Chitosan is such a prospective cationic polysaccharide which has shown number of functions in many fields, including bio medicinal, pharmaceutical, preservative, microbial and others. This article discusses the structure characteristics of chitosan, a number of factors such as degree of polymerization, level of deacetylation, types of quarternisation, installation of various hydrophilic substituents, metal complexation, and combination with other active agents. Biodegradable, non-toxic and non-allergenic nature of chitosan encourages its potential use as a carrier for drug delivery systems in all above mentioned targets. The use of chitosan prodrug conjugates is aimed at the site-specific transport to the target cells use, for example, a spacer tetrapeptide Gly-Phe-Leu-Gly, promotion of drug incorporation into cells via endocytosis, hybridization or synergism of two types of drugs or a drug with a bioactive carrier. The design of chitosan macromolecule prodrugs is also discussed.
- 650 _2
- $a antibakteriální látky $x chemie $x terapeutické užití $7 D000900
- 650 _2
- $a protinádorové látky $x chemie $x terapeutické užití $7 D000970
- 650 _2
- $a antioxidancia $x chemie $x terapeutické užití $7 D000975
- 650 _2
- $a chitosan $x farmakologie $x chemie $x terapeutické užití $7 D048271
- 650 _2
- $a nosiče léků $7 D004337
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a prekurzory léčiv $x farmakologie $x chemie $x terapeutické užití $7 D011355
- 650 _2
- $a financování organizované $7 D005381
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vavříková, Eva $7 xx0126311
- 773 0_
- $t Current Pharmaceutical Design $w MED00007893 $g Roč. 14, č. 13 (2008), s. 1311-1326
- 910 __
- $a ABA008 $b x $y 7
- 990 __
- $a 20110413121613 $b ABA008
- 991 __
- $a 20121127124619 $b ABA008
- 999 __
- $a ok $b bmc $g 831106 $s 695729
- BAS __
- $a 3
- BMC __
- $a 2008 $b 14 $c 13 $d 1311-1326 $m Current pharmaceutical design $n Curr Pharm Des $x MED00007893
- LZP __
- $a 2011-3B/vtme